Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine
This study is ongoing, but not recruiting participants.
Sponsor:
Program for Appropriate Technology in Health
Collaborators:
Institute of Vaccines and Medical Biologicals, Nha Trang
Pasteur Institute, Ho Chi Minh City
Information provided by (Responsible Party):
Program for Appropriate Technology in Health
ClinicalTrials.gov Identifier:
NCT01507779
First received: January 6, 2012
Last updated: July 10, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The study hypothesis is that two 0.5 ml doses of non-adjuvanted whole virion monovalent A/H1N1 influenza vaccine (IVACFLU)-—each dose with an HA content of 15 mcg from A/California/07/2009 (H1N1)-like virus-—will be safe and immunogenic in healthy adults.
| Condition | Intervention | Phase |
|---|---|---|
|
Influenza |
Biological: IVACFLU Other: PBS (Phosphate buffered saline) |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Evaluation of The Safety and Immunogenicity of an Influenza A/H1N1 Vaccine (IVACFLU), Produced by IVAC, in Healthy Adults in Vietnam |
Resource links provided by NLM:
MedlinePlus related topics:
Flu
Drug Information available for:
Influenza Vaccines
U.S. FDA Resources
Further study details as provided by Program for Appropriate Technology in Health:
Primary Outcome Measures:
- Safety Profile [ Time Frame: within three weeks after each dose ] [ Designated as safety issue: Yes ]Immediate reactions occurring within 60 minutes of administration; solicited and unsolicited adverse events occurring through 7 days following any dose; all serious adverse events (SAEs) occurring within 3 weeks of receipt of any dose
- Long terms SAEs [ Time Frame: from 3 weeks to 6 months post-dose 2 ] [ Designated as safety issue: Yes ]Serious adverse events
Secondary Outcome Measures:
- Immunogenicity measure 1 [ Time Frame: three weeks after each dose ] [ Designated as safety issue: No ]serum hemagglutination-inhibition antibodies
- Immunogenicity measure 2 [ Time Frame: three weeks after each dose ] [ Designated as safety issue: No ]serum neutralizing antibodies using microneutralization assay
| Enrollment: | 48 |
| Study Start Date: | April 2012 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Influenza vaccine |
Biological: IVACFLU
IVACFLU is formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009(H1N1)-like virus per 0.5 mL dose
Other Name: whole virion monovalent A/H1N1 influenza vaccine
|
| Placebo Comparator: Placebo |
Other: PBS (Phosphate buffered saline)
Phosphate buffered saline (PBS), pH 7.2, in 0.5 ml single-dose vials.
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 49 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Male or female adult 18 (age of legal consent in Vietnam) through 40 years of age at the enrollment visit.
- Literate and willing to provide written informed consent.
- Free of obvious health problems, as established by the medical history and screening evaluations, including physical examination.
- Capable and willing to complete diary cards and willing to return for all follow-up visits
- For females, willing to utilize reliable birth control measures (intrauterine device, birth control pills, condoms) through the Day 42 visit.
Exclusion Criteria:
- Participation in another clinical trial involving any therapy within the previous three months or planned enrollment in such a trial during the period of this study.
- Receipt of any non-study vaccine within four weeks prior to enrollment or refusal to postpone receipt of such vaccines until after the Day 42 visit.
- Current or recent (within two weeks of enrollment) acute illness with or without fever.
- Receipt of immune globulin or other blood products within three months prior to study enrollment or planned receipt of such products prior to the Day 42 visit.
- Chronic administration (defined as more than 14 consecutively-prescribed days) of immunosuppressants or other immune-modulating therapy within six months prior to study enrollment. (For corticosteroids, this means prednisone or equivalent, >=0.5 mg per kg per day; topical steroids are allowed.)
- History of asthma.
- Hypersensitivity after previous administration of any vaccine.
- Other AE following immunization, at least possibly related to previous receipt of any vaccine.
- Suspected or known hypersensitivity to any of the study vaccine components, including chicken or egg protein.
- Known hypersensitivities (allergies) to food or the natural environment.
- Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, metabolic, neurologic, psychiatric or renal functional abnormality, as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives..
- History of leukemia or any other blood or solid organ cancer.
- History of thrombocytopenic purpura or known bleeding disorder.
- History of seizures.
- Known or suspected immunosuppressed or immunodeficient condition of any kind, including HIV infection.
- Known chronic HBV or HCV infection.
- Known active tuberculosis or symptoms of active tuberculosis, regardless of cause.
- History of chronic alcohol abuse and/or illegal drug use.
- Pregnancy or lactation. (A negative pregnancy test will be required before administration of study vaccine or placebo for all women of childbearing potential.)
- History of Guillain-Barre' Syndrome
- Any condition that, in the opinion of the investigator, would increase the health risk to the subject if he/she participates in the study or would interfere with the evaluation of the study objectives.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01507779
Locations
| Vietnam | |
| Ben Luc Health Center | |
| Ben Luc, Long An, Vietnam | |
Sponsors and Collaborators
Program for Appropriate Technology in Health
Institute of Vaccines and Medical Biologicals, Nha Trang
Pasteur Institute, Ho Chi Minh City
Investigators
| Study Director: | Kathleen M Neuzil, MD, MPH | Program for Appropriate Technology in Health |
| Study Director: | Le V Be, MD, PhD | Institute of Vaccines and Medical Biologicals |
| Principal Investigator: | Ho V Thang, MD, MSc | Pasteur Institute |
More Information
No publications provided
| Responsible Party: | Program for Appropriate Technology in Health |
| ClinicalTrials.gov Identifier: | NCT01507779 History of Changes |
| Other Study ID Numbers: | IVAC-mH1N1-01 |
| Study First Received: | January 6, 2012 |
| Last Updated: | July 10, 2012 |
| Health Authority: | Vietnam: Ministry of Health |
Additional relevant MeSH terms:
|
Influenza, Human Orthomyxoviridae Infections RNA Virus Infections |
Virus Diseases Respiratory Tract Infections Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 23, 2013